Development of mesothelioma-specific oncolytic immunotherapy enabled by immunopeptidomics of murine and human mesothelioma tumors

Jacopo Chiaro, Gabriella Antignani, Sara Feola, Michaela Feodoroff, Beatriz Martins, Hanne Cojoc, Salvatore Russo, Manlio Fusciello, Firas Hamdan, Valentina Ferrari, Daniele Ciampi, Ilkka Ilonen, Jari Räsänen, Mikko Mäyränpää, Jukka Partanen, Satu Koskela, Jarno Honkanen, Jussi Halonen, Lukasz Kuryk, Maria Rescigno, Mikaela Grönholm, Rui M. Branca, Janne Lehtiö and Vincenzo Cerullo ()
Additional contact information
Jacopo Chiaro: University of Helsinki
Gabriella Antignani: University of Helsinki
Sara Feola: University of Helsinki
Michaela Feodoroff: University of Helsinki
Beatriz Martins: University of Helsinki
Hanne Cojoc: Valo Therapeutics Oy
Salvatore Russo: University of Helsinki
Manlio Fusciello: University of Helsinki
Firas Hamdan: University of Helsinki
Valentina Ferrari: Department of Biomedical Sciences, Humanitas University
Daniele Ciampi: Department of Biomedical Sciences, Humanitas University
Ilkka Ilonen: Helsinki University Hospital
Jari Räsänen: Helsinki University Hospital
Mikko Mäyränpää: Helsinki University Hospital
Jukka Partanen: Research & Development Finnish Red Cross Blood Service Helsinki
Satu Koskela: Finnish Red Cross Blood Service Biobank
Jarno Honkanen: Finnish Red Cross Blood Service Biobank
Jussi Halonen: Finnish Red Cross Blood Service Biobank
Lukasz Kuryk: Valo Therapeutics Oy
Maria Rescigno: Department of Biomedical Sciences, Humanitas University
Mikaela Grönholm: University of Helsinki
Rui M. Branca: Karolinska Institutet
Janne Lehtiö: Karolinska Institutet
Vincenzo Cerullo: University of Helsinki

Nature Communications, 2023, vol. 14, issue 1, 1-16

Abstract: Abstract Malignant pleural mesothelioma (MPM) is an aggressive tumor with a poor prognosis. As the available therapeutic options show a lack of efficacy, novel therapeutic strategies are urgently needed. Given its T-cell infiltration, we hypothesized that MPM is a suitable target for therapeutic cancer vaccination. To date, research on mesothelioma has focused on the identification of molecular signatures to better classify and characterize the disease, and little is known about therapeutic targets that engage cytotoxic (CD8+) T cells. In this study we investigate the immunopeptidomic antigen-presented landscape of MPM in both murine (AB12 cell line) and human cell lines (H28, MSTO-211H, H2452, and JL1), as well as in patients’ primary tumors. Applying state-of-the-art immuno-affinity purification methodologies, we identify MHC I-restricted peptides presented on the surface of malignant cells. We characterize in vitro the immunogenicity profile of the eluted peptides using T cells from human healthy donors and cancer patients. Furthermore, we use the most promising peptides to formulate an oncolytic virus-based precision immunotherapy (PeptiCRAd) and test its efficacy in a mouse model of mesothelioma in female mice. Overall, we demonstrate that the use of immunopeptidomic analysis in combination with oncolytic immunotherapy represents a feasible and effective strategy to tackle untreatable tumors.

Date: 2023
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-023-42668-7 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:14:y:2023:i:1:d:10.1038_s41467-023-42668-7

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-023-42668-7

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().